Omnicell (OMCL)
(Delayed Data from NSDQ)
$42.39 USD
+0.88 (2.12%)
Updated Oct 4, 2024 03:59 PM ET
After-Market: $42.36 -0.03 (-0.07%) 7:58 PM ET
1-Strong Buy of 5 1
B Value B Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$42.39 USD
+0.88 (2.12%)
Updated Oct 4, 2024 03:59 PM ET
After-Market: $42.36 -0.03 (-0.07%) 7:58 PM ET
1-Strong Buy of 5 1
B Value B Growth C Momentum B VGM
Zacks News
Medical Info Systems Stock Outlook: Short-Term Pain to Stay
by Zacks Equity Research
The ongoing digital transition is accelerating demand for IT service solutions in healthcare despite legal and regulatory hurdles.
Why Is Omnicell (OMCL) Up 2.6% Since Its Last Earnings Report?
by Zacks Equity Research
Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Omnicell (OMCL) Earnings & Revenues Beat Estimates in Q1
by Zacks Equity Research
Omnicell's (OMCL) first-quarter 2018 performance impresses with year-over-year growth in earnings and revenues.
Omnicell (OMCL) Down 12.7% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Keep Omnicell (OMCL) in Your Portfolio
by Zacks Equity Research
Omnicell (OMCL) continues to progress well with its three-legged strategy. However, escalating costs and tough hospital spending trends pose threats.
Omnicell (OMCL) Earnings Beat, Revenues Miss Estimates in Q4
by Zacks Equity Research
Omnicell's (OMCL) year-over-year growth at both the segments in Q4 is encouraging.
Omnicell's Rising Costs Affect Bottom Line Amid Competition
by Zacks Equity Research
Soft margin scenario is a headwind for Omnicell (OMCL). The company's strategic endeavors such as portfolio expansion, acquisitions and new market growth persistently escalate expenses.
Why Is Omnicell (OMCL) Down 5% Since the Last Earnings Report?
by Zacks Equity Research
Omnicell (OMCL) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
Omnicell's Higher Investments Drive Costs, Competition Rife
by Zacks Equity Research
Omnicell (OMCL) continues to battle escalating costs emanating from several strategies adopted by the company. A tough competitive landscape also acts as a dampener.
Omnicell (OMCL) Earnings Beat, Revenues Miss Estimates in Q3
by Zacks Equity Research
Omnicell (OMCL) witnessed year-over-year growth in revenues on the back of its Medication Adherence segment in Q3.
Omnicell (OMCL) Gains on Product Launches, Global Expansion
by Zacks Equity Research
The market is upbeat about Omnicell's (OMCL) recently-launched XT Series Automated Supply Dispensing Cabinet. The company is also expanding its footprint globally.
Omnicell (OMCL) Gains on Product Launches, Competition Rife
by Zacks Equity Research
Omnicell (OMCL) launches AcuDose software on XT hardware which allows Aesynt customers to fully benefit from XT. The company also launches XT Series Automated Supply Dispensing system.
Omnicell Upgrades Web Portal, Grows in Medication Management
by Zacks Equity Research
Omnicell (OMCL) makes progress in medicare adherence with four new enhancements to its web portal PMAP.
Omnicell (OMCL) Earnings Meet, Revenues Beat Estimates in Q2
by Zacks Equity Research
Omnicell (OMCL) benefited from high XT revenues and strength in IV Solutions in Q2.
Omnicell (OMCL) Catches Eye: Stock Moves 13.5% Higher
by Zacks Equity Research
Omnicell, Inc. (OMCL) moved big last session, as its shares jumped over 13% on the day.
Omnicell (OMCL) Rides on Acquisitions Amid Tough Competition
by Zacks Equity Research
On Jul 4, we issued an updated research report on Mountain View, CA-based Omnicell Inc. (OMCL).
Why Is Omnicell (OMCL) Up 3.3% Since the Last Earnings Report?
by Zacks Equity Research
Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Omnicell (OMCL) Q1 Loss Narrower than Expected, Revenues Lag
by Zacks Equity Research
Omnicell, Inc. (OMCL) reported a loss per share of 29 cents in first-quarter 2017, reflecting a deterioration from the year-ago loss of a penny.
Omnicell's Aesynt Buyout Looks Promising amid Several Woes
by Zacks Equity Research
On Apr 6, we issued an updated research report on Mountain View, CA-based Omnicell Inc. (OMCL).
Why Is Omnicell (OMCL) Up 3% Since the Last Earnings Report?
by Zacks Equity Research
Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Omnicell: Q4 Report Disappoints, Aesynt Buyout Holds Promise
by Zacks Equity Research
On Feb 22, we issued an updated research report on Mountain View, CA-based Omnicell Inc. (OMCL).
Omnicell (OMCL) Q4 Earnings Deteriorate Y/Y, Revenues Miss
by Zacks Equity Research
Omnicell, Inc. (OMCL) reported a breakeven in fourth-quarter 2016 earnings per share (EPS), a deterioration from the year-ago earnings of 5 cents.
Omnicell Partners with DCH Health for Sterile Compounding
by Zacks Equity Research
Omnicell, Inc. (OMCL) recently formed an alliance with West Alabama's community-based health service provider, DCH Health System on sterile compounding operations.
Omnicell Unveils XT Series Automated Dispensing System
by Zacks Equity Research
Omnicell, Inc. (OMCL) recently introduced a new generation of medication and supply automation that is fully integrated with the company's Unity enterprise platform -- XT series.
Omnicell to Buy Ateb, Expand in Adherence Tools Market
by Zacks Equity Research
Omnicell, Inc. (OMCL) recently inked a deal to buy pharmacy-based patient care solution provider Ateb, Inc and its Canadian affiliate, Ateb Canada Ltd.